Bauman G S, Gaspar L E, Fisher B J, Halperin E C, Macdonald D R, Cairncross J G
Department of Oncology, University of Western Ontario, London, Canada.
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9. doi: 10.1016/0360-3016(94)90573-8.
Older age and poor performance status at presentation are unfavorable prognostic factors for patients with glioblastoma multiforme. Some studies suggest a shorter, palliative course of radiotherapy may confer similar benefits as compared to a radical course in such patients. We report a prospective, single arm trial, describing the use of a short-course of radiation in patients with glioblastoma and poor prognostic features.
Twenty-nine patients with pathologically confirmed glioblastoma and age > or = 65 years or with initial KPS < or = 50 were treated with a short-course of whole brain radiotherapy (30 Gy/10 fractions/2 weeks). Computer tomography tumor volume, dexamethasone requirements, Spitzer quality of life index, and Karnofsky performance status were measured pre and 1 month postradiation. Overall survival for the study patients was compared with that of radically treated and supportive care only historical controls.
Indices of tumor response were stable or improved in 60% of patients evaluable 1 month postradiotherapy. Median survival for all study patients was 6 months. Median survivals in similar groups of radically treated and supportive care only patients were 10 and 1 month(s), respectively. A survival advantage for the radical vs. short-course treatment was observed for the subset of patients with a pretreatment KPS > 50.
Elderly patients with a low pretreatment KPS (< or = 50) may be treated adequately with a short, palliative course of radiotherapy. Elderly patients with a higher pretreatment KPS (> 50), however, may benefit from a higher dose radiotherapy regimen.
多形性胶质母细胞瘤患者就诊时年龄较大及表现状态较差是不良预后因素。一些研究表明,与根治性放疗疗程相比,较短的姑息性放疗疗程可能会带来相似的益处。我们报告一项前瞻性单臂试验,描述了在具有不良预后特征的胶质母细胞瘤患者中使用短程放疗的情况。
29例经病理证实为胶质母细胞瘤且年龄≥65岁或初始KPS≤50的患者接受了短程全脑放疗(30 Gy/10次/2周)。在放疗前及放疗后1个月测量计算机断层扫描肿瘤体积、地塞米松需求量、斯皮策生活质量指数和卡诺夫斯基表现状态。将研究患者的总生存期与仅接受根治性治疗和支持性治疗的历史对照患者的总生存期进行比较。
放疗后1个月可评估的患者中,60%的患者肿瘤反应指标稳定或改善。所有研究患者的中位生存期为6个月。仅接受根治性治疗和支持性治疗的类似组患者的中位生存期分别为10个月和1个月。对于预处理KPS>50的患者亚组,观察到根治性治疗与短程治疗相比具有生存优势。
预处理KPS较低(≤50)的老年患者可以通过短程姑息性放疗得到充分治疗。然而,预处理KPS较高(>50)的老年患者可能从更高剂量的放疗方案中获益。